Ashwagandha for Cortisol, Stress and Anxiety: What the Clinical Trials Actually Show

Chronic psychological stress has emerged as one of the most significant accelerators of biological ageing. Chronically elevated cortisol — the primary hormonal output of the HPA axis stress response — shortens telomeres, suppresses immune function, degrades skeletal muscle, impairs sleep architecture, promotes visceral fat accumulation, and drives neuroinflammation. Managing cortisol and stress reactivity is not merely a wellness concern but a foundational anti-ageing lifestyle strategy.

Ashwagandha is the most extensively clinically studied adaptogen for stress and cortisol management — with a body of evidence that has now reached the threshold for provisional clinical recommendations from major psychiatric bodies.

The Systematic Review Evidence Base

A 2021 systematic review identified seven RCTs specifically investigating ashwagandha for stress and anxiety, totalling 491 adults. Six of the seven studies used root-only extracts (three using KSM-66); one used a root-and-leaf extract. All participants were either self-reporting high stress and anxiety or carried a diagnosed anxiety disorder. Supplementation periods ranged from 6 to 8 weeks.

The review found that five of seven studies showed statistically significant improvements in validated stress and anxiety measures compared to placebo. This consistency across multiple independent trials is clinically meaningful — it indicates the effect is replicable rather than a single anomalous result.

The WFSBP Provisional Recommendation

A taskforce of the World Federation of Societies of Biological Psychiatry (WFSBP) and the Canadian Network for Mood and Anxiety Treatments provisionally recommends specific daily doses of ashwagandha root extract for the treatment of generalised anxiety disorder (GAD). This is a significant development — one of very few natural compounds to receive provisional recognition from a major psychiatric professional body for a defined clinical indication. The taskforce notes that the evidence base continues to grow and that stronger recommendations require additional data.

The Landmark KSM-66 Cortisol Trial

The most frequently cited ashwagandha stress trial — Chandrasekhar et al. (2012, Indian Journal of Psychological Medicine) — remains the benchmark for the field:

• Design: Double-blind, randomised, placebo-controlled
• Population: 64 adults with self-reported chronic stress
• Intervention: KSM-66 300mg twice daily (600mg/day total) for 60 days
• Results: 27.9% reduction in serum cortisol vs placebo (p<0.0001); significant improvements in Perceived Stress Scale, General Health Questionnaire, and Depression Anxiety Stress Scale scores; improved self-assessed quality of life

The cortisol reduction is particularly significant because it was measured in serum (blood) — an objective biological marker — not merely a self-reported symptom score. This confirms ashwagandha produces real physiological changes in the HPA axis stress response, not just a placebo-mediated improvement in perceived wellbeing.

The 2024 Shoden RCT: The Strongest Cortisol Data to Date

A 2024 double-blind RCT published in Heliyon (Devarasetti et al.) specifically enrolled participants with clinically elevated cortisol and anxiety — HAMA score above 20 and morning serum cortisol above 25 mcg/dL. This is a more rigorous population than general self-reported stress, because participants had verified biological and psychological pathology at baseline.

60 participants were randomised to Shoden 60mg/day, Shoden 120mg/day, or placebo for 60 days. Results:

• Morning serum cortisol: 66% reduction in the 60mg group and 67% reduction in the 120mg group, vs only 2.2% change in placebo (p<0.0001)
• HAMA anxiety scores: 59% reduction in both treatment groups vs negligible placebo change (p<0.0001)
• Perceived Stress Scale: 53% reduction (60mg) and 62% reduction (120mg)
• Clinical Global Impression — Severity: 72% (60mg) and 68% (120mg) reduction
• Patient Global Impression of Change: 60% improvement in both groups
• No adverse events in either treatment group

The 66–67% cortisol reduction is the largest documented in any ashwagandha RCT to date. The effect was "immediate and sustained" per the nonparametric longitudinal analysis — meaning it was present early in the trial and held throughout. Both the 60mg and 120mg doses produced essentially equivalent results, suggesting the high withanolide concentration (35%) of the Shoden extract is the primary driver rather than the total botanical dose.

The Shoden Anxiety Trial (240mg, Lopresti et al.)

A separate RCT by Lopresti et al. using a different Shoden formulation (240mg/day, standardised to higher withanolide content) found statistically significant reductions in Hamilton Anxiety Rating Scale (HAM-A) scores after 60 days vs placebo, along with significant reductions in morning cortisol and DHEA-S — confirming HPA axis modulation across multiple hormone markers. All participants completed the trial with no adverse events.

Sleep Quality: The Cortisol Connection

Chronically elevated cortisol directly disrupts sleep architecture — particularly the slow-wave deep sleep that drives physical recovery and memory consolidation. By reducing cortisol, ashwagandha improves sleep as a secondary benefit. A 2021 systematic review and meta-analysis of five sleep RCTs (372 adults, 6–12 weeks) found ashwagandha produced a small but statistically significant improvement in sleep quality compared to placebo — with benefits most prominent at 600mg/day for at least 8 weeks and in participants with diagnosed insomnia. A 2024 insomnia-specific RCT confirmed improvements in sleep onset latency, total sleep time, sleep efficiency, and mental alertness on waking.

Mechanism: How Ashwagandha Modulates the Stress Response

Withanolides — primarily withaferin A and withanolide D — modulate the HPA axis through multiple pathways:

• Reducing hypothalamic CRH (corticotropin-releasing hormone) secretion — the upstream signal that drives adrenal cortisol production
• Direct GABA-mimetic activity — withanolides bind to GABA-A receptors, producing anxiolytic effects through the same inhibitory neurotransmitter system targeted by benzodiazepines, but without dependency or cognitive impairment
• Inhibiting the inflammatory NF-kB pathway — which cross-activates the HPA axis; reducing inflammation reduces stress signalling
• Modulating heat shock protein 90 (Hsp90) activity — which regulates glucocorticoid receptor sensitivity

Practical Protocol

• For stress and cortisol: KSM-66 600mg/day (300mg morning + 300mg evening) or Shoden 60–120mg/day; minimum 8 weeks for full effect
• For anxiety and sleep focus: Sensoril 250mg or KSM-66 300–600mg taken in the evening; the calming GABA-mimetic effect is better utilised at night
• With food: Reduces mild GI side effects (loose stools, nausea) that a small proportion of users experience at higher doses
• Cycling: Optional but some practitioners recommend 4–8 weeks on, 1–2 weeks off for long-term use; the 12-month KSM-66 safety study confirms continuous use at 600mg/day is safe over 1 year